PRINCETON, N.J., May 28, 2003 – Therics, Inc., a subsidiary of Tredegar Corporation (NYSE:TG), announced that it received FDA clearance in March to market TheriRidge™ Block, a bone graft substitute indicated and intended for the augmentation of deficient maxillary and mandibular alveolar ridges.

“The FDA’s clearance of the TheriRidge™ product is an important milestone for our company,” said Tom Stribling, president and chief executive officer of Therics. “TheriRidge™ will be the first product manufactured using our breakthrough TheriForm™ microfabrication process to reach the market.” This uniquely microfabricated design of highly biocompatible, synthetic hydroxylapatite is notable for its excellent shaping characteristics and its ability to be secured with screws. This proprietary technology, originally invented at the Massachusetts Institute of Technology (MIT), is distinguished by its ability to spatially control, with extreme precision, the placement of multiple materials into complex three-dimensional constructs. The process provides a high degree of flexibility in the design of product characteristics such as macro and microarchitecture, material composition and internal and external surface textures. Therics has the exclusive license from MIT to develop this technology for FDA-regulated products.

Based in Princeton, N.J., Therics is a developer of three-dimensional printing technology for drug delivery, medical devices and other medical applications.